Form 4: J&J Legal Chief Exercises Options, Vests Shares

Johnson & Johnson's EVP, Chief Legal Officer, Elizabeth Forminard, reported the vesting of restricted and performance share units, along with the exercise of stock options and subsequent tax-related share dispositions.

Summary

• Elizabeth Forminard, EVP, Chief Legal Officer of Johnson & Johnson (JNJ), reported multiple transactions involving company common stock and derivative securities.
• On February 13, 2026, 651 shares of common stock were acquired due to the vesting of Restricted Share Units (RSUs) awarded on February 13, 2023.
• Also on February 13, 2026, 13,706 shares of common stock were acquired due to the vesting of Performance Share Units (PSUs) awarded on February 13, 2023.
• Following these vestings, 314 shares were disposed of at $244.55 and 7,011 shares were disposed of at $244.55 to cover tax obligations.
• On February 15, 2026, 961 shares of common stock were acquired from RSUs awarded on February 15, 2024, and 1,063 shares from RSUs awarded on February 15, 2025, both due to vesting.
• Subsequently, 492 shares were disposed of at $243.45 and 544 shares were disposed of at $243.45 for tax payments.
• On February 15, 2026, Forminard was awarded 27,076 Employee Stock Options with an exercise price of $243.45, vesting in three equal annual installments starting one year from the grant date.
• Additionally, 1,944 Restricted Share Units (RSUs) were awarded on February 15, 2026, vesting in three annual equal installments beginning on the first anniversary of the grant date.
• Following all reported transactions, Elizabeth Forminard beneficially owns 23,568 shares of Common Stock directly.
• Beneficial ownership of derivative securities includes 961 Restricted Share Units (from 2024 award), 2,126 Restricted Share Units (from 2025 award), 27,076 Employee Stock Options, and 1,944 Restricted Share Units (from 2026 award).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and retention mechanisms. The vesting and new grants indicate ongoing alignment of executive interests with company performance, without suggesting any immediate operational or financial shifts.

Positives

• The EVP, Chief Legal Officer, Elizabeth Forminard, received significant compensation through the vesting of 651 Restricted Share Units and 13,706 Performance Share Units from 2023 awards, and 961 and 1,063 Restricted Share Units from 2024 and 2025 awards, respectively.
• Forminard was granted 27,076 new Employee Stock Options and 1,944 new Restricted Share Units, indicating continued long-term incentive alignment with company performance.

Negatives

• A total of 8,361 shares of common stock were disposed of across two transaction dates (314, 7,011, 492, and 544 shares) to cover tax obligations arising from the vesting of equity awards.

Future Outlook

The newly granted Employee Stock Options and Restricted Share Units will vest in three equal annual installments beginning on the first anniversary of their respective grant dates (February 15, 2026).

Industry Context

StockSavvy.ai notes that these transactions represent routine executive compensation activities, common across large publicly traded companies. The vesting of long-term incentive awards and subsequent tax-related sales are standard practices for executives receiving equity-based compensation.

Comparison to Industry Standards

• The structure of equity awards, including Restricted Share Units (RSUs), Performance Share Units (PSUs), and Employee Stock Options, aligns with common executive compensation practices observed in large pharmaceutical and consumer health companies such as Pfizer, Merck, and Procter & Gamble.
• The vesting schedules (typically three annual installments) are standard for long-term incentive plans designed to retain executives and align their interests with long-term shareholder value.
• The disposition of shares to cover tax obligations upon vesting is a widely accepted and common practice, often facilitated through 'sell-to-cover' arrangements, consistent with industry benchmarks.

Stakeholder Impact

• Shareholders: The report details routine executive compensation, which is a standard part of corporate governance and executive retention strategies. It does not indicate any direct impact on shareholder value beyond the normal course of business.
• Employees: The report pertains to executive compensation and does not directly impact the broader employee base.
• Management: The transactions reflect the ongoing compensation structure for the EVP, Chief Legal Officer, aligning her incentives with the company's long-term performance.

Next Steps

• The remaining unvested Restricted Share Units from the February 15, 2024, February 15, 2025, and February 15, 2026 awards will continue to vest in annual installments.
• The newly granted Employee Stock Options will become exercisable in three equal annual installments beginning on the first anniversary of the February 15, 2026 grant date.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, including the vesting of equity awards and the grant of new options and RSUs. Such activities are standard and do not typically provide new fundamental information that would warrant a change in investment recommendation for Johnson & Johnson. The company's overall financial health and strategic outlook remain the primary drivers for investment decisions.

Keywords

Johnson & Johnson, JNJ, Elizabeth Forminard, Insider Transaction, Form 4, Executive Compensation, Restricted Share Units, Performance Share Units, Stock Options, Equity Awards, Share Vesting